Stephen Landy
Overview
Explore the profile of Stephen Landy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landy S, Bahls C, Rapoport A
South Med J
. 2024 Jun;
117(6):350-351.
PMID: 38830592
No abstract available.
2.
Blumenfeld A, Lipton R, Silberstein S, Tepper S, Charleston 4th L, Landy S, et al.
Neurol Ther
. 2023 Aug;
12(5):1533-1551.
PMID: 37542624
Migraine is a neurologic disease with a complex pathophysiology that can be controlled with current treatment options but not cured. Therefore, treatment expectations are highly variable. The concept of migraine...
3.
4.
Kanter K, Gallagher R, Eweje F, Lee A, Gordon D, Landy S, et al.
Harm Reduct J
. 2021 Jul;
18(1):75.
PMID: 34301246
Background: The incidence of opioid-related overdose deaths has been rising for 30 years and has been further exacerbated amidst the COVID-19 pandemic. Naloxone can reverse opioid overdose, lower death rates,...
5.
Landy S, Munjal S, Brand-Schieber E, Rapoport A
J Headache Pain
. 2018 Aug;
19(1):69.
PMID: 30112726
Background: In a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a...
6.
Landy S, Munjal S, Brand-Schieber E, Rapoport A
J Headache Pain
. 2018 Aug;
19(1):70.
PMID: 30112725
Background: DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks. The objective of this study was to evaluate...
7.
Landy S, McGinnis J
Curr Ther Res Clin Exp
. 2014 Mar;
65(4):353-9.
PMID: 24672090
Background: Early treatment with sumatriptan tablets (50 and 100 mg) has been shown to be effective in retrospective and prospective study designs. Despite the efficacy of sumatriptan 50 mg and...
8.
Landy S, Hoagland R, Hoagland D, Saiers J, Reuss G
Ther Adv Neurol Disord
. 2013 Sep;
6(5):279-86.
PMID: 23997813
Objective: Efficacy and tolerability profiles of Treximet [sumatriptan/naproxen sodium combination tablet (SNC)] have been established in clinical trials but have to date been virtually unstudied in pragmatic research. The primary...
9.
Almas M, Tepper S, Landy S, Schweizer E, Ramos E
Cephalalgia
. 2013 Aug;
34(2):126-35.
PMID: 23946318
Objective: The current study evaluated the consistency of eletriptan response. Methods: Using a within-patient crossover design, patients with migraine completed a three-attack, open-label, lead-in period, before being treated, double-blind for...
10.
Landy S, Hoagland R, Hoagland N
Headache
. 2011 Sep;
52(1):133-9.
PMID: 21883200
Objective: This study evaluated the effectiveness of a single fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan-naproxen) using a very early treatment paradigm in migraine patients whose attacks...